Panacea Biotec (PANACEABIO) Fundamentals 2026 — Revenue Analysis | SniperIQ
Panacea Biotec (PANACEABIO) is a India-listed Healthcare company in Biotechnology with a market capitalization of ₹2,829 Crore, trading at ₹461.95 on the NSE. This SniperIQ fundamentals page covers Panacea Biotec's valuation, profitability (net margin -0.8%), revenue (₹640 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Panacea Biotec's market cap?
Panacea Biotec (PANACEABIO) has a market capitalization of approximately ₹2,829 Crore, trading at ₹461.95 on the NSE. Market cap moves with the live share price.
What is Panacea Biotec's P/E ratio?
Panacea Biotec's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Panacea Biotec?
Panacea Biotec runs a net profit margin of -0.8%, a gross margin of 40.0%, and an operating margin of -5.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Panacea Biotec generate?
Panacea Biotec reported revenue of ₹640 Crore for fiscal year 2026, with net income of -₹5 Crore and earnings per share (EPS) of -0.88. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Panacea Biotec pay a dividend?
Panacea Biotec does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Panacea Biotec financially healthy?
Panacea Biotec carries a debt-to-equity ratio of 0.03x and a current ratio of 1.47x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Panacea Biotec a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Panacea Biotec (PANACEABIO) the key facts are: market cap ₹2,829 Crore, revenue ₹640 Crore, 52-week range 292.4-647. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Panacea Biotec's full fundamentals live
Get Panacea Biotec's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.